Edition:
United Kingdom

People: Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

6.21EUR
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
€6.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,948
52-wk High
€9.18
52-wk Low
€4.92

Legault, Pierre 

Mr. Pierre Legault has served as Chairman of the Board of Poxel S.A. since April 18, 2016. He is Member of company's Audit, Remuneration, Business Development, Scientific as well as Strategic and Pricing Committees. He served as Director of the Company between February 1, 2016 and April 18, 2016. He joined Poxel with over 35 years of experience working in the pharmaceutical and biotechnology industry. In 2012, he became Executive Chairman and later became President and CEO of NephroGenex, a North Carolina-based biotechnology company focused on diabetic nephropathy and acute kidney injury. He was responsible for the company's successful IPO to the Nasdaq in 2014 as well as the initiation of a Phase 3 development program. From 2010 to 2012, he was President and CEO of Prosidion Ltd, which specialized in the treatment of diabetes and obesity. In 2009/2010, he was Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. From 2006 to 2007, Pierre was President of Eckerd Pharmacies. Between 1989 and 2005 he held various roles at legacy companies of Sanofi-Aventis, leading up to the position as Worldwide President Dermatology/Dermick which he held from 2003 to 2005. Pierre studied International Finance, Business & Commerce and earned a Masters of Business Administration degree in Marketing from McGill University in Montreal, Canada. He holds also a Bachelor of Business Administration degree from Hautes Etudes Commerciales.

Basic Compensation

Total Annual Compensation, EUR 145,750
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR 3,000
Fiscal Year Total, EUR 148,750

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --